Outpatient Facility Coding Alert - 2003 Issue 32
EVERYONE DISLIKES AWP, BUTDOCS DISLIKE PROPOSED FIXES
Subscribe or sign in to view the full article.
Article Overview
This article examines proposed Medicare payment changes for outpatient prescription drugs covered under Part B, including alternative approaches to reducing overpayments tied to average wholesale price-based reimbursement. It focuses on the expected budget impact, the role of CMS, and the concerns raised by oncology stakeholders and physician groups about practice expense reimbursement and access to care. The piece is relevant to professionals tracking Medicare reimbursement policy, drug payment methodology, and oncology practice economics.
Why This Topic Matters
The article explains a significant Medicare payment policy issue affecting outpatient drug reimbursement and physician practice payments, with implications for federal spending, oncology practices, and beneficiary access to care.
What You Will Learn
- How Medicare Part B outpatient drug payment policy is being reconsidered
- Why CMS is proposing alternative reimbursement approaches
- How oncology stakeholders view the proposed payment changes
- What broader practice expense reimbursement issues are involved
- How the proposed revisions could affect physician participation and access to care
Who Should Read This
- Medical coders
- Billing professionals
- Practice managers
- Oncology administrators
- Compliance professionals
- Health policy analysts
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com